Text: H.Res.1433 — 111th Congress (2009-2010)

Bill text available as:

Shown Here:
Engrossed in House (09/22/2010)


Formatting necessary for an accurate reading of this legislative text may be shown by tags (e.g., <DELETED> or <BOLD>) or may be missing from this TXT display. For complete and accurate display of this text, see the PDF or HTML/XML.




[Congressional Bills 111th Congress]
[From the U.S. Government Printing Office]
[H. Res. 1433 Engrossed in House (EH)]

H. Res. 1433

                In the House of Representatives, U. S.,

                                                    September 22, 2010.
Whereas blood-related cancers currently afflict more than 900,000 people in the 
        United States, with an estimated 150,000 new cases diagnosed each year;
Whereas leukemia, lymphoma, multiple myeloma, myelodys-plastic syndromes, and 
        myeloproliferative disorders will kill more than 50,000 people in the 
        United States this year;
Whereas Congress, in the National Cancer Act, established an aggressive Federal 
        program for the diagnosis, prevention, and treatment of cancer;
Whereas Congress has maintained a steady investment in cancer research to answer 
        basic questions about the causes of cancer and to develop new treatments 
        for cancer;
Whereas the Federal investment in cancer research and control has contributed to 
        important progress in understanding and treating some blood cancers and 
        yielded significant advances in survival for some forms of blood cancer;
Whereas continued investment and innovation is critical to the early diagnosis 
        and the more effective and safer treatment for blood cancers where 
        research and treatment advances have to date been limited;
Whereas strategies to enhance and strengthen the cancer clinical research 
        program and boost participation in clinical trials are necessary to 
        achieve blood cancer treatment advances;
Whereas survivors of blood cancer may experience serious late and long-term 
        effects of their treatment and may need life-long follow-up and 
        survivorship care;
Whereas Congress has provided strong support to blood cancer research and has 
        focused special attention on increasing awareness of blood cancers and 
        intensifying the blood cancer research program;
Whereas the House of Representatives will continue to provide support for 
        research for a cure for leukemia, lymphoma, multiple myeloma, 
        myelodysplastic syndromes, and myeloproliferative disorders; and
Whereas September 2010 would be an appropriate month to designate as Blood 
        Cancer Awareness Month: Now, therefore, be it
    Resolved, That the House of Representatives--
            (1) supports the designation of Blood Cancer Awareness Month to 
        enhance the understanding of blood-related cancers, increase support for 
        funding research to find a cure for blood cancers, encourage studies of 
        the cause and prevention of blood cancers to reduce the number of new 
        cases, and enhance understanding of clinical trials to boost provider 
        and patient participation and accelerate the pace of clinical research;
            (2) encourages participation in voluntary activities to support 
        blood cancer research and education; and
            (3) respectfully requests the Clerk of the House to transmit a copy 
        of this resolution to the American Society of Hematology, the 
        International Myeloma Foundation, the Lymphoma Research Foundation, the 
        Multiple Myeloma Research Foundation, and The Leukemia & Lymphoma 
        Society, voluntary health organizations dedicated to finding a cure for 
        blood cancers.
            Attest:

                                                                          Clerk.